The Claim
In patients with chronic kidney disease, achieving and maintaining serum uric acid levels below 6 mg/dL for more than 80% of follow-up time is associated with greater uric acid reduction, but this level of control does not result in a measurable difference in the rate of kidney function decline over 2.5 years when comparing febuxostat and allopurinol.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with chronic kidney disease, keeping blood uric acid levels below 6 mg/dL for most of the time reduces uric acid levels, but it does not change how quickly kidney function declines over 2.5 years when comparing two common medications, febuxostat and allopurinol.
See the scientific wording
In patients with chronic kidney disease, achieving and maintaining serum uric acid levels below 6 mg/dL for more than 80% of follow-up time is associated with greater uric acid reduction, but this level of control does not translate to a measurable difference in the rate of kidney function decline over 2.5 years when comparing febuxostat and allopurinol.
Lowering uric acid in the blood does not stop the ongoing damage to kidney filters or tubules, so kidney function keeps declining at the same rate no matter how low uric acid goes.
What the research says
1 studyEven though one medicine (febuxostat) lowered uric acid better than the other (allopurinol), both medicines protected the kidneys equally well — so lowering uric acid more doesn’t mean your kidneys slow down their damage any faster.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.